Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meiyu Wu

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|January 9, 2025
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysisOuyang Xie, Meiyu Wu, Andong Li, et al.
Immunotherapy|April 25, 2026
First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysisZixuan Zhang, Kehui Meng, Meiyu Wu, et al.
Frontiers in Pharmacology|May 2, 2022
Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic ReviewMeiyu Wu, Shuxia Qin, Liting Wang, et al.
Molecular Medicine Reports|May 13, 2017
Increased production of human fibroblast growth factor 17 in Escherichia coli and proliferative activity in NIH3T3 cellsMeiyu Wu, Na Song, Jiliang Cheng, et al.
Frontiers in Public Health|August 29, 2022
Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling studyShuxia Qin, Xuehong Wang, Sini Li, et al.
Clinical Rheumatology|February 21, 2025
Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysisOuyang Xie, Meiyu Wu, Andong Li, et al.
Frontiers in Immunology|October 31, 2025
Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in ChinaMeiyu Wu, Yangke Yi, Andong Li, et al.
Clinical and Molecular Hepatology|December 3, 2024
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling studyMeiyu Wu, Jing Ma, Xuehong Wang, et al.
Pharmacoeconomics|September 2, 2024
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling StudyMeiyu Wu, Jing Ma, Sini Li, et al.
RSC Advances|May 11, 2022
Bio-distribution and bio-availability of silver and gold in rat tissues with silver/gold nanorod administrationMeiyu Wu, Liang Chen, Ruiru Li, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Expert Review of Pharmacoeconomics & Outcomes Research|January 9, 2025
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysisOuyang Xie, Meiyu Wu, Andong Li, et al.
Immunotherapy|April 25, 2026
First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysisZixuan Zhang, Kehui Meng, Meiyu Wu, et al.
Frontiers in Pharmacology|May 2, 2022
Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic ReviewMeiyu Wu, Shuxia Qin, Liting Wang, et al.
Molecular Medicine Reports|May 13, 2017
Increased production of human fibroblast growth factor 17 in Escherichia coli and proliferative activity in NIH3T3 cellsMeiyu Wu, Na Song, Jiliang Cheng, et al.
Frontiers in Public Health|August 29, 2022
Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling studyShuxia Qin, Xuehong Wang, Sini Li, et al.
Clinical Rheumatology|February 21, 2025
Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysisOuyang Xie, Meiyu Wu, Andong Li, et al.
Frontiers in Immunology|October 31, 2025
Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in ChinaMeiyu Wu, Yangke Yi, Andong Li, et al.
Clinical and Molecular Hepatology|December 3, 2024
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling studyMeiyu Wu, Jing Ma, Xuehong Wang, et al.
Pharmacoeconomics|September 2, 2024
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling StudyMeiyu Wu, Jing Ma, Sini Li, et al.
RSC Advances|May 11, 2022
Bio-distribution and bio-availability of silver and gold in rat tissues with silver/gold nanorod administrationMeiyu Wu, Liang Chen, Ruiru Li, et al.
Pageof 6